Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Yonsei Med J
Главные авторы: Kwon, Hyeok Chan, Kim, Minyoung Kevin, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Формат: Artigo
Язык:Inglês
Опубликовано: Yonsei University College of Medicine 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://ncbi.nlm.nih.gov/pubmed/32734735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы